Trials / Completed
CompletedNCT01223378
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 413 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BOL-303259-X | ophthalmic solution, various concentrations, once daily (QD) 28 days |
| DRUG | Latanoprost | 0.005% ophthalmic solution, QD 28 days |
Timeline
- Start date
- 2010-12-13
- Primary completion
- 2011-12-20
- Completion
- 2012-06-22
- First posted
- 2010-10-19
- Last updated
- 2018-07-24
- Results posted
- 2018-07-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01223378. Inclusion in this directory is not an endorsement.